CD19 and neoplasm: Blinatumomab, by simultaneously binding CD19 on B-ALL cells and CD3 on T cells, can mediate a direct cross-link between T cells and tumor cells [66,67], resulting in targeted and highly effective tumor cell killing (Figure 1) [68].